Lumateperone Tosylate
Brand names: Caplyta
At a glance
- Medicare prescriptions, 2024
- 112,658
- Medicare drug cost
- $186.0M
- Average cost per prescription
- $1,651
- Clinicians who prescribed it
- 4,522
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
CAPLYTA is indicated for: Treatment of schizophrenia in adults. Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 38.7%
- Psychiatric Nurse Practitioners 38.5%
- Nurse Practitioners 9.5%
- Physician Assistants 5.3%
- Family Medicine 2.9%
- Internal Medicine 2.3%
- Child & Adolescent Psychiatry 1.3%
- Addiction Medicine 0.3%
- Neurology 0.3%
- Geriatric Medicine 0.2%
- General Practice 0.2%
- Mental Health Counselors 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2020–2024
Medicare prescriptions rose 1,590% from 2020 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Intra-Cellular Therapies, Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 10.5 mg | pink capsule, 18 mm | ITI 007 10 5 MG |
| 21 mg | white capsule, 19 mm | ITI 007 21 MG |
| 42 mg | white capsule, 22 mm | ITI 007 42 MG |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $16.8M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) $16.8M
- Janssen Pharmaceuticals, Inc $167
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder Completed · Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
- Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder Completed · Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.